Virax Biolabs Group Limited Ordinary Shares (VRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has a cash flow conversion efficiency ratio of -0.576x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($5.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VRAX equity to assets ratio to measure how much of total assets are equity-financed.
Virax Biolabs Group Limited Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore VRAX operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Virax Biolabs Group Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bkm Industries Limited
NSE:BKMINDST
|
-1.155x |
|
Sileon AB
ST:SILEON
|
-0.285x |
|
Urban-Gro Inc
NASDAQ:UGRO
|
0.056x |
|
Team Internet Group PLC
LSE:TIG
|
0.091x |
|
Investment Friends Capital SE
WAR:IFC
|
0.002x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
|
Antarctica Limited
NSE:ANTGRAPHIC
|
-0.335x |
|
Accesso Technology Group PLC
LSE:ACSO
|
0.116x |
Annual Cash Flow Conversion Efficiency for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Virax Biolabs Group Limited Ordinary Sha.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.46 Million | $-4.56 Million | -0.835x | +31.27% |
| 2024-03-31 | $5.14 Million | $-6.25 Million | -1.216x | -158.97% |
| 2023-03-31 | $8.90 Million | $-4.18 Million | -0.469x | -169.43% |
| 2022-03-31 | $-1.20 Million | $-809.07K | 0.676x | -10.96% |
| 2021-03-31 | $-777.32K | $-590.19K | 0.759x | +23.90% |
| 2020-03-31 | $-1.22 Million | $-744.61K | 0.613x | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more